Allegheny-Singer Research Institute

University of Pittsburgh

Research Institute at Nationwide Children's Hospital

Chau-Ching Liu

Susan M Manzi

Joseph M Ahearn

C Yung Yu

Cell-bound complement activation product (CB-CAP) profiling is combined with determination of C4 gene copy number as biomarkers for lupus and/or pre-lupus diagnosis and monitoring.

Methods and systems using C4 gene copy number and cell-bound complement activation products for identification of lupus and pre-lupus

Methods, systems, and kits useful for determining whether a subject is likely to benefit from therapy with an antibody are provided. In particular aspects, cell-bound complement activation products (CB-CAPs) associated with B lymphocytes may serve as diagnostic biomarkers.

Cell-bound complement activation product assays as companion diagnostics for antibody-based drugs

Cell-bound complement activation product (CB-CAP) profiling and scoring serve as diagnostic biomarkers for patients to determine whether a patient who has not met at least four American College of Rheumatology (or similar e.g. SLICC) criteria for a definite Lupus diagnosis should be classified as exhibiting a pre-existing condition that this document refers to as pre-Lupus. This document also describes methods for determining whether a patient who has been determined to exhibit pre-Lupus has progressed to exhibiting definite Lupus.

Cell-bound complement activation products as diagnostic biomarkers for pre-lupus

Provided are methods, systems, and kits for diagnosing or monitoring systemic lupus erythematosus in an individual. In particular aspects, in a blood sample containing white blood cells from the individual, autoantibodies deposited on or contacting with the surface of a T lymphocyte in the sample are quantitated.

Anti-lymphocyte autoantibodies as diagnostic biomarkers

Cell-bound complement activation product (CB-CAP) profiling and scoring serve as diagnostic biomarkers for patients to determine whether a patient who has not met at least four American College of Rheumatology (or similar e.g. SLICC) criteria for a definite Lupus diagnosis should be classified as exhibiting a pre-existing condition that this document refers to as pre-Lupus.

The invention is related to methods of diagnosing inflammatory diseases or conditions by determining levels of components of the complement pathway on the surface of white blood cells.

Growing community of inventors

Pittsburgh, PA, United States of America

Chau-Ching Liu